Difference between revisions of "Ruxolitinib (Jakafi)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "Also formerly known as INCB018424. ==General information== Class/mechanism: ATP mimetic JAK1 and JAK2 inhibitor <ref name="insert">[http://www.incyte.com/products/uspi_jakafi.pd...")
 
Line 2: Line 2:
  
 
==General information==
 
==General information==
Class/mechanism: ATP mimetic JAK1 and JAK2 inhibitor <ref name="insert">[http://www.incyte.com/products/uspi_jakafi.pdf Ruxolitinib (Jakafi) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ruxolitinib.pdf Ruxolitinib (Jakafi) package insert (locally hosted backup)]</ref>
+
Class/mechanism: kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.<ref name="insert">[http://www.incyte.com/products/uspi_jakafi.pdf Ruxolitinib (Jakafi) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ruxolitinib.pdf Ruxolitinib (Jakafi) package insert (locally hosted backup)]</ref>
 
<br>Route: PO
 
<br>Route: PO
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a

Revision as of 18:25, 5 December 2011

Also formerly known as INCB018424.

General information

Class/mechanism: kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].

Patient drug information

None available at this time.

Regimens

Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)

References